Ovagen is a synthetic Khavinson peptide bioregulator marketed for liver and gastrointestinal support, and users primarily cite liver health & hepatic function as their reason for use (based on a single low‑confidence report). Most users report taking about 25 mg per day, with a observed range of 25–50 mg, while some clinicians advise 200 µg daily orally; neither group specifies timing or cycling. The peptide has no FDA‑approved indication, so all human consumption is off‑label or compounded, and the sole available report did not describe any side effects.
Data last updated
Measured on 3 of 6 axes
Evidence shape
The evidence for Ovagen is animal‑only, reflecting preclinical mechanistic research and a total of zero human published studies. Breadth shows a single indication mapped, depth records zero registered trials, and quality confirms no completed trials. Consequently, there is a clear absence of human clinical data, with no published studies, no trial results, and no human evidence available to date.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
Symptom-relevant clinical or community evidence has not been captured for this peptide yet.
price offers can be sorted by column · 1 out-of-stock offer not shown
Some links are affiliate links. This never affects our rankings or inclusion.
How Ovagen is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
According to the sole source listed for Ovagen in the Clinician practice tier, the peptide is administered orally at a dose of 200 mcg taken once each day, with no cycling protocol specified.
The typical dose reported is 25 mg, with a range of 25–50 mg per oral pill; frequency of administration was not specified in the source.